%0 Journal Article %A Godel Michel %A Robain François %A Kojovic Nada %A Franchini Martina %A Wood de Wilde Hilary %A Schaer Marie %T Distinct patterns of treatment response using the Early Start Denver Model with young children with autism spectrum disorder: a cluster analysis %D 2021 %R 10.1101/2021.04.05.21254908 %J medRxiv %P 2021.04.05.21254908 %X Evidence-based, early intervention significantly improves developmental outcome in young children with autism. Despite having an overall positive impact on most children, there is high interindividual heterogeneity of response to treatment, and it is currently not possible to predict whether a child will make significant progress in early intervention based on their profile of symptoms at diagnosis. In this study, we analyze developmental trajectories of preschoolers with autism who received 2 years of intervention using the Early Start Denver Model (ESDM) approach in Geneva, Switzerland (n = 47). Our aim was to identify early predictors of response to treatment. We applied cluster analysis to distinguish between 3 subgroups based on cognitive level at intake, and rates of cognitive change over the course of treatment. The first subgroup of children only had a mild cognitive delay at intake, and nearly no cognitive delay by the end of treatment (Higher Cognitive at baseline: HC). The children in the two other subgroups all presented with severe cognitive delay at baseline, however, they had two very different patterns of response to treatment. The majority significantly improved developmental scores within their first year of intervention (Optimal Responders: OptR). Whereas a minority of children showed little to no improvement over the course of treatment (Minimal Responders: MinR). Our findings suggest that children who end up having a more optimal two-year treatment outcome show rapid developmental improvement. Inversely, less significant progress by the sixth month of intervention may predict a less optimal short-term response to treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Swiss National Foundation Synapsy Grant Number 51NF40 – 185897 and the Swiss National Foundation for Scientific Research Grant Number 323630–191227 to M.G., and #163859 and #190084 to M.S. And by the Fondation Pole Autisme (https://www.pole-autisme.ch). The funders were not involved in this study and had no role other than to provide financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from the parents of all participants included in the study. Swissethics - Commission d éthique Suisse relative à la recherche sur l être humain approved this study (Protocole 12-163/Psy 12-014), referred under the number PB_2016-01880 and accepted on september the 25th, 2012.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated in the current study are available from the corresponding author on reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2021/05/28/2021.04.05.21254908.full.pdf